Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Vétoquinol    VETO   FR0004186856

VÉTOQUINOL

(VETO)
  Report  
Delayed Quote. Delayed Euronext Paris - 10/18 11:12:32 am
57 EUR   +1.06%
10/16VÉTOQUINOL : 3rd quarter earnings
CO
07/25VÉTOQUINOL : Half-year results
CO
05/31VÉTOQUINOL : Ex-dividend day for final dividend
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

VETOQUINOL : PUBLISHES ITS REGISTRATION DOCUMENT AND ITS ANNUAL FINANCIAL REPORT RELATIVE TO FISCAL YEAR 2018 (FRENCH VERSION)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/29/2019 | 11:53am EDT

For immediate release

Lure (France), April 29, 2019

VETOQUINOL PUBLISHES ITS REGISTRATION DOCUMENT

AND ITS ANNUAL FINANCIAL REPORT

RELATIVE TO FISCAL YEAR 2018 (FRENCH VERSION)

The registration document of Vetoquinol relative to fiscal year 2018, including the annual financial report relative to fiscal year 2018, was filed with the Autorité des marchés financiers ("the AMF") on April 29, 2019.

It can be read or downloaded on the websites of:

Vetoquinol (www.vetoquinol.com)

AMF (www.amf-france.org)

It is also available to the public free of charge upon simple request:

by mail:

Vetoquinol

Communication financière

Magny-Vernois - BP 189 - 70204 Lure Cedex - France

by e-mail:

relations.investisseurs@vetoquinol.com

by phone:

+33 (0)3 84 62 59 88

The registration document integrates among other:

the report of the Board of directors on the corporate governance and on the internal control established upon provisions of article L. 225-37 of the French Commercial code;

the management report;

the declaration of extra-financial performance;

the statutory auditors' reports;

the information relative to the fees paid to the statutory auditors.

Next update: First half 2019 results, July 25, 2019 after market close

About Vetoquinol

Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets.

As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. At December 31, 2018 Vetoquinol employs 2,132 people.

Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).

For further information, go to: www.vetoquinol.com.

For more information, contact:

VETOQUINOL

KEIMA COMMUNICATION

Investor Relations

Investor and Media Relations

Fanny TOILLON

Emmanuel Dovergne

Tel.: +33 (0)3 84 62 59 88

Tel.: +33 (0)1 56 43 44 63

relations.investisseurs@vetoquinol.com

emmanuel.dovergne@keima.fr

VETOQUINOL - 34 rue du Chêne Sainte Anne - Magny-Vernois - 70204 Lure Cedex - France

www.vetoquinol.com

Disclaimer

Vétoquinol SA published this content on 29 April 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 29 April 2019 15:52:07 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VÉTOQUINOL
10/16VÉTOQUINOL : 3rd quarter earnings
CO
07/25VÉTOQUINOL : Half-year results
CO
05/31VÉTOQUINOL : Ex-dividend day for final dividend
FA
05/06VETOQUINOL : Programme de rachat - November 2017 (french)
PU
04/29VETOQUINOL : Publishes its registration document and its annual financial report..
PU
04/17Q1 2019 SALES : €90.9 million (up 3.7%)
PU
04/17VÉTOQUINOL : 1st quarter earnings
CO
04/12VETOQUINOL SA : quaterly sales release
03/20VÉTOQUINOL : Annual results
CO
03/18VETOQUINOL SA : annual earnings release
More news
Financials (EUR)
Sales 2019 390 M
EBIT 2019 48,5 M
Net income 2019 32,9 M
Finance 2019 104 M
Yield 2019 0,82%
P/E ratio 2019 20,6x
P/E ratio 2020 16,7x
EV / Sales2019 1,46x
EV / Sales2020 1,32x
Capitalization 675 M
Chart VÉTOQUINOL
Duration : Period :
Vétoquinol Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VÉTOQUINOL
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 68,17  €
Last Close Price 57,00  €
Spread / Highest target 35,1%
Spread / Average Target 19,6%
Spread / Lowest Target 6,14%
EPS Revisions
Managers
NameTitle
Matthieu Frechin Chief Executive Officer & Non-Independent Director
Étienne Frechin Chairman
Jean-Yves Ravinet Group Chief Operating Officer
Régis Vimal du Monteil Group Director-Finance & Legal Affairs
Jean Deleforge Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
VÉTOQUINOL12.20%752
ZOETIS49.78%61 185
ELANCO ANIMAL HEALTH INCORPORATED-16.81%9 784
DECHRA PHARMACEUTICALS26.86%3 464
JINYU BIO-TECHNOLOGY CO., LTD.49.34%3 038
VIRBAC99.03%2 127